Houston, Texas-based LyondellBasell Industries N.V. (LYB) is one of the leading plastics, chemical, and refining companies globally. Its products are used in electronics, automotive parts, packaging, construction materials, and biofuels. With a market cap of $13.9 billion, LyondellBasell’s operations span North America, Europe, Indo-Pacific, and internationally.
LyondellBasell has substantially underperformed the broader market over the past year. LYB stock prices have plunged 38.7% on a YTD basis and 45.5% over the past 52 weeks, compared to the S&P 500 Index’s ($SPX) 14.6% gains in 2025 and 12.6% returns over the past year.
Narrowing the focus, LyondellBasell has also underperformed the sector-focused Materials Select Sector SPDR Fund’s (XLB) 4.1% uptick in 2025 and 5.5% decline over the past 52 weeks.
LyondellBasell’s stock prices gained 2.7% in the trading session following the release of its better-than-expected Q3 results on Oct. 31. The company has continued to face pressure on its topline due to softness in the chemicals industry. Its topline for the quarter dropped 10.2% year-over-year to $7.7 billion, but surpassed the Street’s expectations by 3.1%. Meanwhile, its adjusted EPS plunged 47.1% year-over-year to $1.01, but exceeded the consensus estimates by 26.3%.
For the full fiscal 2025, ending in December, analysts expect LYB to deliver an adjusted EPS of $2.47, down 61.4% year-over-year. The company has a mixed earnings surprise history. While it missed the Street’s bottom-line estimates twice over the past four quarters, it met or surpassed the projections on two other occasions.
Among the 20 analysts covering the LYB stock, the consensus rating is a “Hold.” That’s based on three “Strong Buys,” one “Moderate Buy,” 12 “Holds,” and four “Strong Sells.”
This configuration is slightly less pessimistic than a month ago, when three analysts gave “Strong Sell” recommendations.
On Nov. 11, Evercore ISI Group analyst Stephen Richardson maintained an “In-Line” rating on LYB and lowered the price target from $65 to $57.
Bio-Techne’s mean price target of $55.63 represents a 22.2% premium to current price levels. Meanwhile, the street-high target of $80 suggests a 75.7% upside potential.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
- Ray Dalio Warns the Next Big Debt Crisis Won’t Come From Banks. It’ll Come From Governments.
- This ‘Strong Buy’ Dividend Stock Yields 8%. Should You Add It to Your Portfolio?
- Who Is Phil Clifton? Michael Burry Names Successor as Famed Investor Deregisters Hedge Fund.
- Michael Burry Slams NVDA, PLTR, META, ORCL. Here’s What the Charts Say About His Tech-Focused ‘Big Short.’